

journal homepage: www.elsevier.com/locate/febsopenbio

MicroRNAs downregulated in neuropathic pain regulate MeCP2 and BDNF related to pain sensitivity

Melissa T. Manners^a, Yuzhen Tian^a, Zhaolan Zhou^b, Seena K. Ajit^{a,*}^a Pharmacology & Physiology, Drexel University College of Medicine, Philadelphia, USA^b Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, USA

ARTICLE INFO

Article history:

Received 25 May 2015

Revised 11 August 2015

Accepted 16 August 2015

Keywords:

MeCP2

miRNA

Neuropathic pain

BDNF

ABSTRACT

Nerve injury induces chronic pain and dysregulation of microRNAs in dorsal root ganglia (DRG). Several downregulated microRNAs are predicted to target *MeCP2*. *MECP2* mutations cause Rett syndrome and these patients report decreased pain perception. We confirmed MeCP2 upregulation in DRG following nerve injury and repression of MeCP2 by miRNAs *in vitro*. MeCP2 regulates brain-derived neurotrophic factor (BDNF) and downregulation of MeCP2 by microRNAs decreased *Bdnf* *in vitro*. MeCP2 T158A mice exhibited reduced mechanical sensitivity and *Mecp2*-null and MeCP2 T158A mice have decreased *Bdnf* in DRG. MeCP2-mediated regulation of *Bdnf* in the DRG could contribute to altered pain sensitivity.

© 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Chronic pain is a prevalent, disabling health condition affecting more than 100 million people in the United States [1]. Neuropathic pain caused by injury or dysfunction of the nervous system can result in peripheral and central sensitization, a state of hyperexcitability due to reduction in threshold and an amplification in the responsiveness of nociceptors [2]. Elucidation of signaling pathways underlying pain hypersensitivity is crucial in improving our understanding of molecular mechanisms that drive plasticity in the nervous system promoting the development and maintenance of chronic pain states [3]. Animal models of neuropathic pain have been pivotal in the exploration of molecular mechanisms of pain underlying nerve injury [4]. Our miRNA profiling study in the dorsal root ganglion (DRG) from a nerve injury model identified

63 miRNAs differentially regulated compared to sham controls [5]. Bioinformatic prediction indicates 15 downregulated miRNAs are predicted to target the 3' untranslated region (3'UTR) of *MeCP2*. Translational repression of MeCP2 mediated by binding of miRNAs to the 3'UTR has been reported [6–10].

MeCP2 binds methylated DNA, and together with co-repressors or transcriptional activators, mediates downstream changes in gene expression either directly or by altering chromatin structure [11,12]. Mutations in the X-linked methyl-CpG-binding protein 2 (*MECP2*) gene cause Rett syndrome (RTT) [13,14]. Decreased pain perception is commonly reported in children with RTT [15,16]. The abnormal sensitivity can be as high as 75%, with a potential relationship between hyposensitivity and specific mutations in the *MECP2* gene [15]. The observations from RTT patients indicate that decreased functional MeCP2 contributes either directly or indirectly to reduced pain sensitivity. Since reduced pain sensitivity observed in RTT patients results from a decrease in functional MeCP2 protein, we postulated that a decrease in miRNAs that bind and repress translation of MeCP2 will cause an increase in MeCP2 levels and thus contribute to hypersensitivity.

MeCP2 can mediate downstream transcriptional changes of a large number of genes and depending on its interacting protein partners and target genes, MeCP2 can act either as an activator or repressor [12,17]. MeCP2 is a known regulator of *Bdnf* [18], a neurotrophin important in both neuronal development and peripheral pain mechanisms [19]. BDNF levels in the hypothalamus correlated with MeCP2 levels, with lower levels in

Abbreviations: ATF3, activating transcription factor 3; BDNF, brain derived neurotrophic factor; CFA, complete Freund's adjuvant; DRG, dorsal root ganglia; L4/L5, 4th or 5th lumbar vertebra; MeCP2, methyl-CpG-binding protein 2; MeCP2 T158A/Y, male MeCP2 T158A knock in mouse; RTT, Rett syndrome; SNI, spared nerve injury; T158A, threonine 158 conversion to alanine; TrkB, tropomyosin receptor kinase B; 3'UTR, three prime untranslated region; -/Y, male *Mecp2*-null mouse; +/Y, male wild-type littermate control for either MeCP2 T158A knock in mouse or *Mecp2*-null mouse

* Corresponding author at: Pharmacology & Physiology, Drexel University College of Medicine, 245 North 15th Street, Mail Stop 488, Philadelphia, PA 19102, USA. Tel.: +1 215 762 2218; fax: +1 215 762 2299.

E-mail address: seena.ajit@drexelmed.edu (S.K. Ajit).

<http://dx.doi.org/10.1016/j.fob.2015.08.010>

2211-5463/© 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Mecp2-null mice and higher levels in *MECP2* overexpressing mice compared to controls [12]. The role of BDNF in both inflammatory and neuropathic pain is well established [20–23]. Here we investigated if miRNAs downregulated in a rodent model of neuropathic pain that modulate MeCP2 expression, can induce changes in *Bdnf* levels in Neuro-2a cells.

Several mouse models have been generated for investigating MeCP2 function [24] including alteration of the endogenous *Mecp2* gene, or introduction of the human *MECP2* gene with RTT-associated mutations. One of the most common mutations observed in RTT is in amino acid T158, located at the C terminus of the methyl-CpG binding domain of MeCP2. It has been reported that 70.6% of patients with this mutation have decreased pain sensitivity [15]. The phenotype of MeCP2 T158A knockin mice resembles developmental symptoms found in RTT patients [25]. MeCP2 T158A mice showed a reduction in MeCP2 binding to methylated DNA and a decrease in MeCP2 protein stability. Female *Mecp2*^{+/-} mice and a conditional mouse allele that expresses 50% of the wild-type level of MeCP2 had a slower reaction to a conductive heat stimulus [26,27]. We sought to assess the pain sensitivity of MeCP2 T158A mice as well as expression of *Bdnf* to test our hypothesis that MeCP2 plays a role in mediating pain sensitivity and confirm the functional implication of a mutation in the methyl binding domain.

Thus here we sought to determine whether miRNAs downregulated after nerve injury regulate MeCP2 and hence modulate *Bdnf* expression, contributing to hypersensitivity. We used MeCP2 T158A mice to determine if a point mutation in the methyl binding domain can attenuate pain sensitivity, and we measured expression of *Bdnf* in the DRG from MeCP2 T158A mice and *Mecp2*-null mice to determine the regulatory role of MeCP2 on *Bdnf* in the DRG.

2. Materials and methods

2.1. Cell culture, transfection and luciferase reporter assay

HEK293 and Neuro-2a cells obtained from American Type Culture Collection (ATCC) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum at 37 °C in 5% CO₂. For the reporter assay HEK293 cells were co-transfected with precursor miRNA or anti-miRNA plasmid (GeneCopeia) and luciferase reporter plasmid containing the 3'UTR of *Mecp2* using Lipofectamine 2000 (Life Technologies) for 48 h. The ~8.5 kb 3'UTR sequence of *Mecp2* was cloned downstream of the luciferase reporter gene as 4 constructs of ~2 kb fragment each (GeneCopeia). The fragment with the miRNA target sequence of interest (1–2210 bp or 6360–8591 bp) was co-transfected with corresponding miRNA. The Luc-Pair Duo-Luciferase assay (GeneCopeia) was used to measure firefly and renilla luciferase according to the manufacturer's instructions. Firefly luciferase measurements normalized to renilla was used as a transfection control. For monitoring changes in endogenous MeCP2, Neuro-2a cells were transfected with precursor miRNA or anti-miRNA plasmid (GeneCopeia) using X-tremeGENE HP (Roche) for 48 h.

2.2. Western blot

Protein from Neuro-2a cells or DRG was isolated using radioimmunoprecipitation assay buffer (Thermo Scientific). For western blotting, 20 µg protein lysates were resolved by a 4–12% SDS-PAGE gel, transferred to the nitrocellulose membrane. The membranes were probed with MeCP2 antibody [25] at 1:3000 dilution overnight. Chemiluminescence was detected using FluorChem M System (Protein Simple). The membrane was also probed with goat

anti-rabbit GAPDH-HRP (1:2000 dilution, Santa Cruz) as a loading control. Quantification was determined using UN-SCAN-IT software, MeCP2 expression was normalized to GAPDH.

2.3. Immunocytochemistry

Neuro-2a cells grown on 12mm glass coverslips were transfected with miRNA precursor plasmids with GFP using X-tremeGENE HP DNA transfection reagent for 48 h. Cells were fixed in 4% formaldehyde and blocked in 10% normal goat serum followed by a 3 h incubation in 1:200 anti-MeCP2 antibody (mentioned above). Anti-Rabbit-IgG Atto 647N secondary antibody (Sigma) was used for detection of MeCP2. Coverslips were mounted using Vectashield Mounting Medium with DAPI (Vector Laboratories). Images were acquired using the 60× objective on the Olympus 1 × 81 confocal microscope and Fluoview FV10-ASW software. Image J was used for quantification. MeCP2 levels were normalized to DAPI staining of the nucleus. Transfected (GFP positive) and untransfected (GFP negative) cells were then compared.

2.4. Quantitative RT-PCR

RNA was purified from Neuro-2a cells, DRG collected from spared nerve injury (SNI) model, sham control, *Mecp2*-null, MeCP2 T158A and the corresponding wild-type littermate mice using the mirVana RNA isolation kit (Life technologies). cDNA synthesis and qRT-PCR were performed as previously described [28]. The Assay ID for the Taqman primer probes used were Mm01193535_M1 (*Mecp2*) and Mm04230607_s1 (*Bdnf*). *Gapdh* was used as the normalizer and a *t*-test was used to perform statistical analysis.

2.5. Animal model of neuropathic pain

The care and use of all mice were approved by the Institutional Animal Care & Use Committee of Drexel University College of Medicine. The SNI model was generated using 8-week old C57BL/6 male mice (Taconic) as previously described [29,30]. Briefly, mice were anesthetized with isoflurane during surgery. The common peroneal and tibial nerves of the left paw were ligated, 2–4 mm of the nerve was sectioned and removed distal to ligation. Sham mice underwent the same surgical procedures as the SNI group without ligation and sectioning. Development of mechanical hypersensitivity was assessed using von Frey filaments [30] and the Mann–Whitney *U* test was used to calculate significance. L4 and L5 DRG on the ipsilateral side of surgery were collected 4 weeks post SNI surgery at 12 weeks of age.

2.6. Behavior studies using MeCP2 T158A mice

Male MeCP2 T158A mice and wild-type littermates were purchased from Jackson laboratories (Bar Harbor, Maine). Thermal and mechanical sensitivity were determined using the Hargreaves' method [31] and von Frey filaments respectively. Behavior testing and tissue collection was conducted at 12 weeks of age. Mann–Whitney *U* test was used for statistical analysis.

3. Results

3.1. Chronic neuropathic pain induced MeCP2 upregulation in DRG

MeCP2 has been predicted to play a role in pain and modulation of MeCP2 has been observed in various inflammatory and neuropathic pain models [32,33]. To investigate whether MeCP2 expression is altered in a neuropathic pain state, we generated an SNI

model. We confirmed increased mechanical sensitivity and data 4 weeks post-surgery on 12 week old mice is shown in Fig. 1a. Though there was a trend, the increase in *Mecp2* mRNA in DRG after nerve injury was not significant (Fig. 1b). However, there was a significant increase in MeCP2 protein in the SNI model (Fig. 1c). This increased expression of MeCP2 in a neuropathic pain state could in part be mediated by the reduced expression of miRNAs predicted to target *Mecp2* in the DRG [5]. We therefore sought to determine the regulatory role of a selected subset of miRNAs on MeCP2 expression.

3.2. Confirmation of miRNAs predicted to target *Mecp2* 3'UTR

To experimentally validate the bioinformatics prediction of miRNAs targeting the *Mecp2* 3'UTR, a luciferase reporter assay was performed. We tested a subset of miRNAs that were decreased in the DRG from a nerve injury model based on seed sequence complementarity, varying positions throughout the 3'UTR, the presence of multiple binding sites, and those not predicted to target *Bdnf* mRNA. Reduction in luciferase expression and therefore, miRNA binding to the *Mecp2* 3'UTR was validated for miR-19a, miR-301 and miR-132 (Fig. 2), while miR-17 and miR-181 did not reduce luciferase activity (data not shown).

3.3. MeCP2 expression is modulated by miRNAs

To further evaluate regulation of MeCP2 expression from miRNA binding, Neuro-2a cells were transfected with precursor miRNAs or antagonirs that are inhibitors of endogenous miRNAs. Our data indicate that transfection of Neuro-2a cells with miR-19a, miR-301 and miR-132 did not decrease *Mecp2* mRNA (Fig. 3a) but reduced MeCP2 protein as shown in western blot (Fig. 3b) and immunocytochemistry of endogenous MeCP2 in cells transfected with individual miRNAs (Fig. 3d–f). The antagonirs of miR-301 and miR-132 increased MeCP2 expression (Fig. 3c). We did not observe an increase in MeCP2 protein after the transfection of miR-19a inhibitor which could be due to a low endogenous level of miR-19a in Neuro-2a cells, the inhibition of which would not lead to the modulation of MeCP2 expression. Since we did not observe significant changes in *Mecp2* mRNA after over expressing miRNAs, we conclude that *Mecp2* regulation by miRNAs tested is mediated by translational repression and not through RNA degradation.

3.4. miRNA-mediated decrease of MeCP2 lead to concomitant reduction in *Bdnf*

To determine if miRNA mediated regulation of MeCP2 affects expression of the MeCP2 target genes, we measured *Bdnf* mRNA




Fig. 2. miRNA binding to MeCP2 3'UTR. Luciferase assay showing miR-132, miR-19a, and miR-301 binding to the 3'UTR of *Mecp2*. The luciferase activity was measured 24 h after miRNA transfection. The data expressed as percentage of control is the average of 3 independent experiments. Statistically significant difference from control was calculated using one way ANOVA and Student *t*-test, *p* value **<0.01, ***<0.001.

after transfecting Neuro-2a cells with miR-19a, miR-301 and miR-132. Fig. 4a shows that there was reduction in *Bdnf* transcripts after overexpressing miRNAs. Additionally, inhibiting endogenous miR-132 and miR-301 resulted in increased *Bdnf* transcript (Fig. 4b). The miRNAs used in this study were confirmed to target the *Mecp2* 3'UTR, but are not predicted to bind the *Bdnf* 3'UTR. Thus, the reduced expression of *Bdnf* can be a direct consequence of miRNA mediated regulation of MeCP2.

3.5. MeCP2 T158A mice have reduced mechanical sensitivity

Mice expressing 50% of the wild-type level of MeCP2 and female *Mecp2*^{+/−} mice have reduced thermal sensitivity [26,34]. We wanted to further investigate the effect of MeCP2 mutations on pain behavior by assessing nociception in MeCP2 T158A mice. We observed that MeCP2 T158A mice have reduced mechanical sensitivity compared to wild-type littermate control mice (Fig. 5a). We found no significant changes in thermal sensitivity as determined by Hargreaves' method between MeCP2 T158A and wild-type littermate control mice (data not shown). These results indicate a role for MeCP2 in mediating mechanical sensitivity.

3.6. *Bdnf* is downregulated in the DRG of *Mecp2*-null mice and MeCP2 T158A mice

Several studies using mouse models have shown a direct correlation between MeCP2 and *Bdnf* expression in the brain indicating




Fig. 1. MeCP2 expression in DRG 4 weeks after SNI or sham surgery in 12 weeks old mice. (A) von Frey filaments used to assess paw withdrawal threshold confirmed that mice were hypersensitive 4 weeks post SNI surgery ($n = 10$). Significance was determined using Mann–Whitney *U* test p value <0.001. (B) Taqman analysis of *Mecp2* mRNA showed a trend toward increased expression that was not significant in SNI model compared to sham control ($n = 7$). *Gapdh* was used as the normalizer. (C) Western blot analysis of MeCP2 expression in DRG showed a significant increase in SNI model, determined using Student *t*-test, p value *<0.05. Tissue from 9 animals was pooled into 3 samples ($n = 3$). Protein expression was normalized to GAPDH.




Fig. 3. Regulation of MeCP2 by miRNAs. (A) Taqman analysis of *Mecp2* in Neuro-2a cells 48 h after miRNA transfection showed no significant reduction in mRNA ($n = 3$). (B) Western blot analysis after transfection of Neuro-2a cells with miR-301, miR-132 and miR-19a significantly reduced MeCP2 protein ($n = 3$). (C) MeCP2 expression increased when cells were transfected with anti-miR (miRNA inhibitors) for miR-301 and miR-132; ($n = 3$, representative blot shown). (D and E) Immunocytochemistry and quantification for MeCP2 in Neuro-2a cells transfected with miR-132. (F and G) Immunocytochemistry and quantification for MeCP2 in Neuro-2a cells transfected with miR-19a. (H and I) Immunocytochemistry and quantification for MeCP2 in Neuro-2a cells transfected with miR-301. MeCP2 levels were normalized to DAPI staining of the nucleus and the graph represents MeCP2 expression relative to untransfected cells. Representative images are shown, $n = 3$. Significance was determined using Student *t*-test, p value * <0.05 , ** <0.001 *** <0.001 .




Fig. 4. MeCP2 mediated changes in *Bdnf* transcripts. (A) miRNA-mediated reduction of MeCP2 expression decreased *Bdnf* mRNA in Neuro-2a cells 48 h after miRNA transfection as determined by Taqman analysis. (B) Antagomirs, inhibitors of endogenous miRNAs, increased *Bdnf* mRNA. *Gapdh* was used as the normalizer, $n = 3$. Significance determined using Student *t*-test, p value * <0.05 , ** <0.001 .




Fig. 5. MeCP2 T158A knockin mice have decreased mechanical sensitivity and lower *Bdnf*. (A) Mechanical sensitivity measured by von Frey filaments showed an increase in withdrawal threshold in 12 weeks old MeCP2 T158A mice, indicating hyposensitivity compared to wild-type littermate controls ($n = 5$ for MeCP2 T158A mice and $n = 7$ for wild-type littermate). Statistically significant difference was determined using the Mann–Whitney *U* test; there was a significant reduction in withdrawal threshold in the ipsilateral paw p value * <0.02 . (B) DRG from *Mecp2*-null mice and (C) MeCP2 T158A mice has significantly lower *Bdnf* mRNA compared to wild-type littermates, ($n = 6$). (D) *Bdnf* was also lower in MeCP2 T158A mice compared to wild-type littermates after SNI surgery. Significance determined using Student *t*-test, p value * <0.05 ($n = 3$ for both MeCP2 T158A mice and wild-type littermate).

that MeCP2 regulates *Bdnf* [18]. We examined *Bdnf* expression in DRG from *Mecp2*-null mice. Fig. 5b shows a reduction in *Bdnf* mRNA levels in *Mecp2*-null mice compared to control. Thus MeCP2 mediated regulation of *Bdnf* expression in DRG appears to be similar to that observed in brain. We then investigated *Bdnf* levels in DRG from MeCP2 T158A mice to determine if a loss of function mutation would yield a similar result (Fig. 5c). We observed a decrease in *Bdnf* mRNA in the DRG of MeCP2 T158A mice as was previously reported in the brain [25]. These results indicate that in DRG, the role of MeCP2 as an activator is important for precise

regulation of *Bdnf* and alteration of *Bdnf* in DRG may be a contributing factor leading to aberrant pain sensitivity in RTT.

3.7. *Bdnf* is decreased in MeCP2 T158A SNI model compared to wild-type SNI model mice

To determine how changes in MeCP2 in the DRG affect pain behavior, we generated an SNI model using MeCP2 T158A mice and wild-type littermate controls. Unfortunately, conducting mechanical and thermal sensitivity assessment post-SNI surgery

was not possible in the MeCP2 T158A mouse; post-surgical over grooming behavior resulted in injuries compared to wild-type littermates. We collected the DRG from MeCP2 T158A mice 4-weeks post SNI and from wild-type SNI mice, and measured *Bdnf* transcripts. After nerve injury, MeCP2 T158A mice have decreased *Bdnf* compared to wild-type littermate control mice (Fig. 5d). *Bdnf* levels did not differ significantly between SNI and sham MeCP2 T158A mice (data not shown). This suggests that in the absence of fully functional MeCP2, the upregulation of *Bdnf* is impaired even after nerve injury, again suggesting the regulatory role of MeCP2 on *Bdnf*.

4. Discussion

The role of MeCP2 in the development and function of the central nervous system is well established and neuronal dysfunction contributes to symptoms associated with RTT [14,35]. Previous studies investigating the role of MeCP2 in pain have shown differences in expression pattern of MeCP2 in DRG and spinal cord from various rodent models of pain. An increase in MeCP2 has been associated with the development of neuropathic pain in the chronic constriction injury model in rats 14 days after injury [36]. MeCP2 is known to play an important role in signaling in the superficial dorsal horn upon induction of peripheral inflammation by injecting complete Freund's adjuvant (CFA) in rat ankle joint. This study showed that phosphorylation of MeCP2 led to the release of DNA-bound MeCP2, relieving the repression on a few MeCP2 target genes in lamina I neurons. These genes were upregulated rapidly in this model of inflammatory pain [37]. MeCP2 expression was increased in the superficial dorsal horn 7 days following CFA injection in the ankle joint but decreased 7 days following SNI [38]. This study also showed that MeCP2 levels were decreased in activating transcription factor 3 (ATF3)-positive neurons in DRG after SNI [38]. Another report showed an increase in *Mecp2* transcripts in the spinal cord 2 h after peripheral injection of formalin [9]. Upregulation of MeCP2 in the central nucleus of the amygdala was reported in the CFA model [39]. Differences in models, tissues, and time points can influence gene expression and so we performed qPCR and western blot analysis for MeCP2 using DRG from a mouse SNI model of neuropathic pain 4 weeks after surgery. We observed a significant increase of MeCP2 protein in DRG.

MeCP2 can regulate microRNAs (miRNAs) [40] and dysregulation of miRNAs was observed in the cerebella of *Mecp2*-null mice [41]. miRNA-mediated alteration of MeCP2 was reported to alter pain threshold in wild-type mice. miR-124a was downregulated in spinal cord after peripheral noxious stimulation with formalin and this was associated with an increase in *Mecp2* mRNA [9]. Intravenous administration of a miRNA-124a inhibitor enhanced the nociceptive behavior and miRNA-124a mimic significantly reduced formalin-induced inflammatory pain. In addition to confirming that *Mecp2* is a target for miR-124a, this study showed administration of miR-124a mimic induced a decrease in *Mecp2* mRNA and miR-124a inhibitor enhanced MeCP2 levels in the spinal cord [9]. In another study, intrathecal miR-124 treatment reversed persistent hyperalgesia induced by carrageenan and prevented the development of mechanical allodynia in the SNI model of chronic neuropathic pain [42]. Thus future studies investigating the role of miRNAs validated to target *Mecp2* will be beneficial in confirming their role in pain.

Our previous study investigating miRNA changes in DRG identified several miRNAs predicted to target *Mecp2* 3'UTR. The miRNAs were downregulated after nerve injury and because of the expected inverse correlation in expression between miRNAs and genes they regulate, we selected a subset of 5 miRNAs for further studies. Of these, miR-19a, miR-301 and miR-132 were confirmed

to bind and regulate *Mecp2* by translational repression. miR-132 is a previously validated miRNA for MeCP2 [6] and we included it as a positive control. This reduction of MeCP2 protein resulted in decreased *Bdnf*, indicating that activation by MeCP2 is an important mechanism of regulation for normal expression of BDNF. Our findings that inhibition of miRNA-mediated repression increased MeCP2 and *Bdnf* is similar to what was reported for miR-132 in cultured rat neurons [6].

Alterations in BDNF expression is a common phenomenon in both RTT and pain states, albeit in reverse direction. BDNF is an important modulator of sensory neurotransmission in nociceptive pathways both at spinal and supraspinal levels and has an important role in the development of central sensitization that underlies many forms of hyperalgesia [19]. Many of the biological effects of BDNF are mediated by the high affinity postsynaptic receptor Tropomyosin receptor kinase B (TrkB). TrkB signaling contributes to both the induction and maintenance of injury induced persistent pain and Trk inhibitors have been developed for the treatment of pain [43]. In addition to correlation of BDNF levels in the hypothalamus with MeCP2 levels, with lower levels in *Mecp2*-null mice and higher levels in *MECP2* overexpressing mice compared to controls [12], disruption of total BDNF levels and secretion in *Mecp2*-null neurons indicate that functional MeCP2 is important for BDNF expression [44]. BDNF-related therapies have shown a reversal of cardiorespiratory deficits in *Mecp2*-null mice and is being pursued for the amelioration of RTT-like neurological symptoms in mouse models [18]. Our qPCR studies showed that *Bdnf* levels in the DRG were downregulated in both *Mecp2*-null and MeCP2 T158A mice. Thus the reduction in endogenous *Bdnf* could be one of the contributing factors leading to decreased pain sensitivity. After SNI surgery, lower levels of *Bdnf* in MeCP2 T158A mice compared to wild-type mice further indicates that increased *Bdnf* in the DRG after nerve injury is in part mediated by MeCP2. A recent study investigating the role of MeCP2 in pain regulation and morphine reward showed that MeCP2 and histone dimethyltransferase G9a induce a transcriptional de-repression of *Bdnf* in central nucleus of the amygdala, promoting pain behavior through BDNF upregulation [39]. Thus in addition to direct activation of *Bdnf*, MeCP2 in its role as a transcriptional repressor of G9a, further enhance BDNF levels in chronic pain.

Our studies showed that mice with the loss of function mutation, T158, have reduced mechanical sensitivity compared to wild-type littermates. *Mecp2*^{Flox/y} mice expressing 50% of the wild-type level of MeCP2 and female *Mecp2*^{-/-} mice have reduced thermal sensitivity in a hot plate test [26,34] but there are no reports to date investigating their mechanical sensitivity. Our assessment of thermally induced nociception using the Hargreaves' method showed no differences in MeCP2 T158A mice and wild-type littermates. Differences in the thermal sensitivity could be due to the specific mutation of MeCP2 or the method of measuring thermal sensitivity. Since BDNF release in dorsal horn in neuropathic pain model is associated with thermal hyperalgesia [45,46], we postulate that other modes of action may be playing a role in mediating mechanical sensitivity in T158A mice. Studies investigating function of DRG neurons in naïve animals have shown that delivering BDNF directly to DRGs induced mechanical allodynia. Conversely, after nerve injury direct administration of anti-BDNF antibody to injured DRG attenuated mechanical allodynia [47]. MeCP2 and BDNF are expressed in microglia and astrocytes in addition to neurons and additional studies are needed to determine the contribution of these different cell types in modulating aberrant pain sensation in MeCP2 T158A mice. A recent study investigated the role of miR-183, a miRNA that was significantly downregulated in the ipsilateral L5 DRG after SNL [48]. Intrathecal administration of miR-183 attenuated mechanical allodynia and this was associated with the downregulation of BDNF transcripts

in DRG [48]. This study demonstrated that downregulation of BDNF in DRG was correlated with attenuated mechanical allodynia in SNL model of neuropathic pain. Our data shows that mutations in *Mecp2* can reduce mechanical pain sensitivity. Since MeCP2 can mediate downstream transcriptional changes of a large number of genes, we cannot rule out the contribution of other dysregulated genes (due to T158A mutation in methyl binding domain of MeCP2) to aberrant pain sensitivity in MeCP2 T158A mice.

In conclusion, our results indicate that miRNA-mediated regulation of MeCP2 can contribute to the mechanical hypersensitivity observed in neuropathic pain models by altering BDNF in the DRG.

Neuropathic pain induces MeCP2 and BDNF expression in the DRG; conversely, RTT mouse models lacking or expressing reduced levels of MeCP2 have decreased *Bdnf* that can contribute to mechanical hyposensitivity. Further investigations including *in vivo* delivery of miRNAs targeting *Mecp2* followed by characterization of pain behavior and investigation of MeCP2 expression and downstream targets in naïve mice, RTT and pain models can provide insights on therapeutic options for both pain and RTT.

Author contributions

S.A. conceived and supervised the study; M.M. and S.A. designed experiments; M.M. and Y.T. performed experiments; M.M. analyzed the data; Z.Z. provided reagents and critical input regarding the study design; M.M. and S.A. wrote the manuscript; Z.Z. made manuscript revisions.

Acknowledgments

This work was supported by grants from Commonwealth Universal Research Enhancement (CURE), Pennsylvania Department of Health and Rita Allen Foundation to Seena Ajit.

The funding agency had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

References

- Gereau, R.W., Sluka, K.A., Maixner, W., Savage, S.R., Price, T.J., Murinson, B.B., Sullivan, M.D. and Fillingim, R.B. (2014) A pain research agenda for the 21st century. *J. Pain* 15, 1203–1214.
- von Hehn, C.A., Baron, R. and Woolf, C.J. (2012) Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. *Neuron* 73, 638–652.
- Basbaum, A.I., Bautista, D.M., Scherrer, G. and Julius, D. (2009) Cellular and molecular mechanisms of pain. *Cell* 139, 267–284.
- Mogil, J.S., Davis, K.D. and Derbyshire, S.W. (2010) The necessity of animal models in pain research. *Pain* 151, 12–17.
- von Schack, D. et al. (2011) Dynamic changes in the microRNA expression profile reveal multiple regulatory mechanisms in the spinal nerve ligation model of neuropathic pain. *PLoS ONE* 6, e17670.
- Klein, M.E., Lioy, D.T., Ma, L., Impey, S., Mandel, G. and Goodman, R.H. (2007) Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. *Nat. Neurosci.* 10, 1513–1514.
- Wada, R., Akiyama, Y., Hashimoto, Y., Fukamachi, H. and Yuasa, Y. (2010) MiR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. *Int. J. Cancer* 127, 1106–1114.
- Han, K. et al. (2013) Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p. *Genes Dev.* 27, 485–490.
- Kynast, K.L., Russe, O.Q., Möser, C.V., Geisslinger, G. and Niederberger, E. (2013) Modulation of central nervous system-specific microRNA-124a alters the inflammatory response in the formalin test in mice. *Pain* 154, 368–376.
- Kuhn, D.E. et al. (2010) Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human down syndrome brains. *J. Biol. Chem.* 285, 1529–1543.
- Bird, A. (2008) The methyl-CpG-binding protein MeCP2 and neurological disease. *Biochem. Soc. Trans.* 36, 575–583.
- Chahrouh, M., Jung, S.Y., Shaw, C., Zhou, X., Wong, S.T., Qin, J. and Zoghbi, H.Y. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science* 320, 1224–1229.
- Samaco, R.C. and Neul, J.L. (2011) Complexities of Rett syndrome and MeCP2. *J. Neurosci.* 31, 7951–7959.
- Guy, J., Cheval, H., Selfridge, J. and Bird, A. (2011) The role of MeCP2 in the brain. *Annu. Rev. Cell Dev. Biol.* 27, 631–652.
- Downs, J., Geranton, S.M., Bebbington, A., Jacoby, P., Bahi-Buisson, N., Ravine, D. and Leonard, H. (2010) Linking MECP2 and pain sensitivity: the example of Rett syndrome. *Am. J. Med. Genet. A* 152A, 1197–1205.
- Peters, S.U., Hundley, R.J., Wilson, A.K., Warren, Z., Vehorn, A., Carvalho, C.M.B., Lupski, J.R. and Ramocki, M.B. (2013) The behavioral phenotype in MECP2 duplication syndrome: a comparison with idiopathic autism. *Autism Res.* 6, 42–50.
- Zachariah, R.M. and Rastegar, M. (2012) Linking epigenetics to human disease and Rett syndrome: the emerging novel and challenging concepts in MeCP2 research. *Neural Plast.* 2012, 415825.
- Li, W. and Pozzo-Miller, L. (2014) BDNF deregulation in Rett syndrome. *Neuropharmacology* 76, 737–746 (Part C).
- Merighi, A., Salio, C., Ghirri, A., Lossi, L., Ferrini, F., Betelli, C. and Bardoni, R. (2008) BDNF as a pain modulator. *Prog. Neurobiol.* 85, 297–317.
- Ha, S.O., Kim, J.K., Hong, H.S., Kim, D.S. and Cho, H.J. (2001) Expression of brain-derived neurotrophic factor in rat dorsal root ganglia, spinal cord and gracile nuclei in experimental models of neuropathic pain. *Neuroscience* 107, 301–309.
- Lin, Y.-T., Ro, L.-S., Wang, H.-L. and Chen, J.-C. (2011) Up-regulation of dorsal root ganglia BDNF and trkB receptor in inflammatory pain: an *in vivo* and *in vitro* study. *J. Neuroinflammation* 8, 126.
- Obata, K. and Noguchi, K. (2006) BDNF in sensory neurons and chronic pain. *Neurosci. Res.* 55, 1–10.
- Uchida, H., Matsushita, Y. and Ueda, H. (2013) Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: implications in the development of neuropathic pain. *Neuroscience* 240, 147–154.
- Calfa, G., Percy, A.K. and Pozzo-Miller, L. (2011) Experimental models of Rett syndrome based on *Mecp2* dysfunction. *Exp. Biol. Med.* (Maywood) 236, 3–19.
- Goffin, D. et al. (2012) Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. *Nat. Neurosci.* 15, 274–283.
- Samaco, R.C. et al. (2008) A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. *Hum. Mol. Genet.* 17, 1718–1727.
- Samaco, R.C., McGraw, C.M., Ward, C.S., Sun, Y., Neul, J.L. and Zoghbi, H.Y. (2012) Female *Mecp2*^{+/-} mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. *Hum. Mol. Genet.*
- Capasso, K. et al. (2014) Effect of histone deacetylase inhibitor JNJ-26481585 in pain. *J. Mol. Neurosci.*, 1–9.
- Decosterd, I. and Woolf, C.J. (2000) Spared nerve injury: an animal model of persistent peripheral neuropathic pain. *Pain* 87, 149–158.
- Gao, R., Gao, X., Xia, J., Tian, Y., Barrett, J.E., Dai, Y. and Hu, H. (2013) Potent analgesic effects of a store-operated calcium channel inhibitor. *Pain* 154, 2034–2044.
- Bennett, J.G. (2001). Animal Models of Pain. In *Methods in Pain Research*, CRC Press.
- Geranton, S.M. (2012) Targeting epigenetic mechanisms for pain relief. *Curr. Opin. Pharmacol.* 12, 35–41.
- Crow, M., Denk, F. and McMahon, S. (2013) Genes and epigenetic processes as prospective pain targets. *Genome Med.* 5, 12.
- Samaco, R.C., McGraw, C.M., Ward, C.S., Sun, Y., Neul, J.L. and Zoghbi, H.Y. (2013) Female *Mecp2*^{+/-} mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. *Hum. Mol. Genet.* 22, 96–109.
- Na, E.S. and Monteggia, L.M. (2011) The role of MeCP2 in CNS development and function. *Horm. Behav.* 59, 364–368.
- Wang, Y., Liu, C., Guo, Q.-L., Yan, J.-Q., Zhu, X.-Y., Huang, C.-S. and Zou, W.-Y. (2011) Intrathecal 5-azacytidine inhibits global DNA methylation and methyl-CpG-binding protein 2 expression and alleviates neuropathic pain in rats following chronic constriction injury. *Brain Res.* 1418, 64–69.
- Geranton, S.M., Morenilla-Palao, C. and Hunt, S.P. (2007) A role for transcriptional repressor methyl-CpG-binding protein 2 and plasticity-related gene serum- and glucocorticoid-inducible kinase 1 in the induction of inflammatory pain states. *J. Neurosci.* 27, 6163–6173.
- Tochiki, K.K., Cunningham, J., Hunt, S.P. and Geranton, S.M. (2012) The expression of spinal methyl-CpG-binding protein 2, DNA methyltransferases and histone deacetylases is modulated in persistent pain states. *Mol. Pain* 8, 14.
- Zhang, Z., Tao, W., Hou, Y.Y., Wang, W., Kenny, P.J. and Pan, Z.Z. (2014) MeCP2 repression of G9a in regulation of pain and morphine reward. *J. Neurosci.* 34, 9076–9087.
- Szulwach, K.E. et al. (2010) Cross talk between microRNA and epigenetic regulation in adult neurogenesis. *J. Cell Biol.* 189, 127–141.
- Wu, H. et al. (2010) Genome-wide analysis reveals methyl-CpG-binding protein 2-dependent regulation of microRNAs in a mouse model of Rett syndrome. *Proc. Natl. Acad. Sci. U.S.A.* 107, 18161–18166.
- Willemen, H., Huo, X.-J., Mao-Ying, Q.-L., Zijlstra, J., Heijnen, C. and Kavelaars, A. (2012) MicroRNA-124 as a novel treatment for persistent hyperalgesia. *J. Neuroinflammation* 9, 143.
- Wang, T., Yu, D. and Lamb, M.L. (2009) Trk kinase inhibitors as new treatments for cancer and pain. *Expert Opin. Ther. Pat.* 19, 305–319.

- [44] Wang, H., Chan, S.-A., Ogier, M., Hellard, D., Wang, Q., Smith, C. and Katz, D. M. (2006) Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in *Mecp2* null mice. *J. Neurosci.* 26, 10911–10915.
- [45] Miletic, G. and Miletic, V. (2002) Increases in the concentration of brain derived neurotrophic factor in the lumbar spinal dorsal horn are associated with pain behavior following chronic constriction injury in rats. *Neurosci. Lett.* 319, 137–140.
- [46] Pezet, S. and McMahon, S.B. (2006) Neurotrophins: mediators and modulators of pain. *Annu. Rev. Neurosci.* 29, 507–538.
- [47] Zhou, X.F., Deng, Y.S., Xian, C.J. and Zhong, J.H. (2000) Neurotrophins from dorsal root ganglia trigger allodynia after spinal nerve injury in rats. *Eur. J. Neurosci.* 12, 100–105.
- [48] Lin, C.-R., Chen, K.-H., Yang, C.-H., Huang, H.-W. and Sheen-Chen, S.-M. (2014) Intrathecal miR-183 delivery suppresses mechanical allodynia in mononeuropathic rats. *Eur. J. Neurosci.* 39, 1682–1689.